Drug intelligence / Profile preview

4MT-A

Development stage: Preclinical
Lead developer: 4M Therapeutics
Modality: Small Molecules

Overview

4MT-A is a novel, small molecule glycogen synthase kinase 3 beta (GSK3β) inhibitor developed by 4M Therapeutics Inc. for neuropsychiatric and neurodegenerative conditions. Preclinical studies have shown that 4MT-A, along with 4MT-B, can attenuate amphetamine-induced positive appetitive ultrasonic vocalizations, a validated model of positive affective state, demonstrating comparable efficacy to lithium at significantly lower concentrations. The drug aims to target key pathways in the brain to address conditions like bipolar disorder and agitation in Alzheimer's disease.

Targets

GSK3 (Glycogen synthase kinase 3 beta)

Beyond the preview

Go deeper on 4MT-A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 4MT-A.

Explore the full profile